Federal State Unitary Enterprise "Moscow Endocrine Plant", subordinate to the Ministry of Industry and Trade of Russia, by the end of December 2020 will organize the release of the medicinal drug "Nadroparin Calcium, solution for subcutaneous administration of 9500 IU of anti-Xa/ml of 0.3 ml, 0.4 ml, 0.6 ml , 0.8 ml, and 1.0 ml in pre-filled syringes", and in the first quarter of 2021 - the release of the medicinal drug "Enoxaparin sodium, solution for injection 10,000 IU of anti-Xa/ml of 0.2 ml, 0.4 ml, 0.6 ml, 0.8 ml, and 1.0 ml in pre-filled syringes."
These drugs are heparin derivatives used for the prevention of thromboembolic complications in the treatment of coronavirus infection in accordance with the Interim Recommendations of the Ministry of Health of Russia for the diagnosis and treatment of COVID-19 (Version 9).
Also in the first quarter of 2021, the Moscow Endocrine Plant will double the production of the drug "Heparin sodium, solution for intravenous and subcutaneous administration of 5000 IU/ml, in ampoules of 5 ml No. 5" - said the First Deputy Minister of Industry and Trade of the Russian Federation Sergey Tsyb during a joint visit with the Head of Moscow City Investment and Industrial Policy Department Alexander Prokhorov to the Enterprise.
“We are working here as a united front - the Government of the Russian Federation, the Ministry of Industry, and the Department of Industry of the city of Moscow, we are solving the tasks that we are facing today to increase the production of the anticovid group of drugs that are being administered today,” emphasized Sergey Tsyb.
During 2020, the Company upgraded production lines in order to organize its own production of Midazolam and Sibazon, which are in demand in the regions of the Russian Federation, in new dosage forms convenient for use in children with generalized tonic, clonic and tonic-clonic seizures.
Until now, similar drugs were not produced in Russia and were purchased from abroad. The enterprise will begin its own production of these medicinal products at the end of December 2020, after the work on state registration is completed.
FSUE "Moscow Endocrine Plant" carries out an important social mission in the context of state policy in the field of ensuring the availability of necessary drugs for the citizens of the country.
Comment type is not specified in the component properties.